{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:17:58Z","timestamp":1792545478765,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,6,4]],"date-time":"2027-06-04T00:00:00Z","timestamp":1812067200000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100013131","name":"Walter Reed National Military Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013131","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.urology.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:44:41Z","timestamp":1774939481000},"page":"8-13","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["IncobotulinumtoxinA Versus OnabotulinumtoxinA for Treatment of Overactive Bladder Syndrome: A Randomized Single-blinded Non-inferiority Trial"],"prefix":"10.1016","volume":"212","author":[{"given":"Anna S.","family":"Trikhacheva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara J.","family":"Hamade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan D.","family":"Gisseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Vaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.","family":"Dengler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2026.03.040_bib1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00345-002-0301-4","article-title":"Prevalence and burden of overactive bladder in the United States","volume":"20","author":"Stewart","year":"2003","journal-title":"World J Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib2","first-page":"8","article-title":"The burden of overactive bladder on US public health","volume":"11","author":"Reynolds","year":"2016","journal-title":"Curr Bladder\u00a0Dysfunct Rep"},{"key":"10.1016\/j.urology.2026.03.040_bib3","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1016\/j.juro.2012.09.079","article-title":"Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA\/SUFU guideline","volume":"188","author":"Gormley","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib4","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a\u00a0double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib5","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo-controlled trial of botulinum A toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"issue":"S1","key":"10.1016\/j.urology.2026.03.040_bib7","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032372","article-title":"Botox (onabotulinumtoxinA) mechanism of action","volume":"102","author":"Brin","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.urology.2026.03.040_bib8","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4103\/0019-5154.60343","article-title":"Botulinum toxin","volume":"55","author":"Nigam","year":"2010","journal-title":"Indian J Dermatol"},{"key":"10.1016\/j.urology.2026.03.040_bib9","first-page":"31","article-title":"Comparison and overview of currently available neurotoxins","volume":"7","author":"Walker","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.1016\/j.urology.2026.03.040_bib10","unstructured":"BOTOX\u00ae Prescribing Information, June 2019."},{"key":"10.1016\/j.urology.2026.03.040_bib11","year":"2021"},{"key":"10.1016\/j.urology.2026.03.040_bib12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1468-1331.2009.02879.x","article-title":"Xeomin: an innovative new botulinum toxin type A","volume":"16","author":"Frevert","year":"2009","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.urology.2026.03.040_bib13","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3390\/toxins8030065","article-title":"Conversion ratio between Botox\u00ae, Dysport\u00ae, and Xeomin\u00ae in clinical practice","volume":"8","author":"Scaglione","year":"2016","journal-title":"Toxins"},{"key":"10.1016\/j.urology.2026.03.040_bib14","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00702-004-0234-8","article-title":"Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers","volume":"112","author":"Jost","year":"2005","journal-title":"J Neural Transm"},{"key":"10.1016\/j.urology.2026.03.040_bib15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2146\/ajhp140276","article-title":"Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia","volume":"72","author":"Kazerooni","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.urology.2026.03.040_bib16","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/j.apmr.2021.10.027","article-title":"Cost efficiency analysis for spasticity management based on physician botulinum toxin prescribing habits","volume":"103","author":"Kazerooni","year":"2022","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.urology.2026.03.040_bib17","first-page":"478","article-title":"Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population","volume":"27","author":"Kazerooni","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.urology.2026.03.040_bib18","first-page":"E520","article-title":"The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity","volume":"14","author":"Asafu-Adjei","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.urology.2026.03.040_bib19","doi-asserted-by":"crossref","first-page":"625","DOI":"10.23736\/S2724-6051.21.04227-2","article-title":"IncobotulinumtoxinA versus OnabotulinumtoxinA intradetrusor injections in patients with neurogenic detrusor overactivity incontinence: a double-blind, randomized, non-inferiority trial","volume":"74","author":"Giannantoni","year":"2022","journal-title":"Minerva Urol Nephrol"},{"key":"10.1016\/j.urology.2026.03.040_bib20","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/jocd.12949","article-title":"Two different types of botulinum toxins: Is there a difference in efficacy and longevity?","volume":"18","author":"Shome","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.urology.2026.03.040_bib21","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","article-title":"Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence","volume":"367","author":"Visco","year":"2012","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.urology.2026.03.040_bib22","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1001\/jama.2016.14617","article-title":"OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial","volume":"316","author":"Amundsen","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2026.03.040_bib23","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/SPV.0000000000001020","article-title":"Comparison of 100 U With 200 U of Intradetrusor OnabotulinumToxinA for nonneurogenic urgency incontinence","volume":"27","author":"Hendrickson","year":"2021","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"10.1016\/j.urology.2026.03.040_bib24","first-page":"207","article-title":"Variability of 24-hour voiding diary variables among asymptomatic women","volume":"169","author":"Fitzgerald","year":"2003","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib26","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/mds.23254","article-title":"Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (Botox\u00ae) across multiple indications","volume":"25","author":"Naumann","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.urology.2026.03.040_bib27","unstructured":"U.S. Department of Veterans Affairs Office of Procurement, Acquisition and Logistics. Pharmaceutical Prices April 3, 2024.Accessed April 14, 2024\u3008https:\/\/www.va.gov\/opal\/nac\/fss\/pharmprices.asp\u3009."},{"key":"10.1016\/j.urology.2026.03.040_bib28","unstructured":"CDC Compliant Refrigerators. Health Care Logistics Inc. 2025. Accessed March 22, 2026. \u3008https:\/\/www.gohcl.com\/cold-storage-and-accessories\/refrigerators\/cdc-compliant-refrigerators\u3009."},{"key":"10.1016\/j.urology.2026.03.040_bib29","unstructured":"How Many Watts Does a Refrigerator Use? Energy Sage. Updated February 24, 2026. Accessed March 22, 2026. \u3008https:\/\/www.energysage.com\/electricity\/house-watts\/how-many-watts-does-a-refrigerator-use\/\u3009."},{"key":"10.1016\/j.urology.2026.03.040_bib30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","article-title":"Durable efficacy and safety of long-term OnabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study","volume":"196","author":"Nitti","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2026.03.040_bib31","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1007\/s00415-022-10995-2","article-title":"Time to onset and duration of botulinum toxin efficacy in movement disorders","volume":"269","author":"Ledda","year":"2022","journal-title":"J Neurol"},{"key":"10.1016\/j.urology.2026.03.040_bib32","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1080\/03007995.2021.1965975","article-title":"Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-na\u00cfve subjects","volume":"37","author":"Mitsikostas","year":"2021","journal-title":"Curr Med Res Opin"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526002219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429526002219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T08:53:10Z","timestamp":1780563190000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429526002219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"alternative-id":["S0090429526002219"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2026.03.040","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IncobotulinumtoxinA Versus OnabotulinumtoxinA for Treatment of Overactive Bladder Syndrome: A Randomized Single-blinded Non-inferiority Trial","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}